

---

**Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS consortium scoring system**

---

*Thomas Prebet,<sup>1,2</sup> Pierre Fenaux,<sup>2,3</sup> and Norbert Vey<sup>2,4</sup> on behalf of the Groupe Francophone des Myelodysplasies*

*<sup>1</sup>Smilow Cancer center at Yale New Haven Hospital, CT, USA; <sup>2</sup>Groupe Francophone des myélodysplasies, Hôpital Saint Louis, Paris, France; <sup>3</sup>Service Hematologie Senior, Hôpital Saint Louis, Paris, France; and <sup>4</sup>Service Hematologie 2, Institut Paoli-Calmettes, Marseille, France*

*Correspondence: [thomas.prebet@yale.edu](mailto:thomas.prebet@yale.edu)*

*doi:10.3324/haematol.2016.150714*

**Supplemental table 1**

<b>Variable</b>	<b>Relative weight</b>
ECOG PS >1	1 pt
Very poor cytogenetics	1 pt
Bone marrow blast percentage >20%	0.75 pt
RBC transfusion dependency: yes	0.75 pt
Age 65-74 years	0.5 pt
Age 75-84 years	1 pt
Age 85+ years	2 pts
Platelet count 30-99 G/l	0.5 pt
Platelet count below 30 G/l	1 pt